Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis's Jakavi gets EU polycythemia vera indication

This article was originally published in Scrip

Executive Summary

The European Commission has approved Novartis's oral JAK 1 and 2 tyrosine kinase inhibitor Jakavi (ruxolitinib) for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea, making it the first targeted treatment approved in the EU for this patient population. The approval adds to that already received for the product in the EU and elsewhere for myelofibrosis, and follows the December supplemental approval for polycythemia vera in the US, where it is marketed by Incyte as Jakafi. The polycythemia vera approvals were based on data from the Phase III RESPONSE trial in which the drug significantly improved hematocrit as well as symptom control and reduced spleen size in patients with the rare and incurable blood cancer who were resistant to or intolerant of hydroxyurea. The EU application received a positive opinion from the CHMP in January.

You may also be interested in...

ESMO: Sanofi/Regeneron’s Latecomer Anti-PD-1 Libtayo Looking Likely In NSCLC

Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.

Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate

Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.

ESMO: A Tale Of Two CDK 4/6 Inhibitors With monarchE Success and Failure For PALLAS

Two different outcomes for two different CD4/6 inhibitors – Eli Lilly’s Verzenio and Pfizer’s Ibrance – put the Lilly drug on track to be a new standard of care in high-risk early stage HR+, HER2-negative breast cancer. Novartis’s Kisqali could follow.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts